Patents

2019
  • Preparation of heterocyclyl urea derivatives as modulators of tryptophan catabolism useful in treatment of diseases WO2019229464 More
  • Preparation of substituted sulfonyl azacycles as modulators of hedgehog (Hh) signalling pathway WO2019043372 More
  • Preparation of substituted cyclyl-sulfonamides as modulators of hedgehog (Hh) signalling pathway WO2019043373 More
  • Preparation of pyrrolopyrimidine and pyrrolopyridine derivatives as ASK1 inhibitors WO2019012284 More
  • Preparation of heterocyclyl urea derivatives as modulators of tryptophan catabolism useful in treatment of diseases WO2019229464 More
2018
  • Modulators of Hedgehog (Hh) signalling pathway WO2018078360 More
2017
  • Preparation of seco macrolide aminoglycosides for use in the treatment of prophylaxis More
2011
  • New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases WO2011131749 More
2010
  • Tricyclic azabicyclo [4.1.0] heptane derivatives as inhibitors of serotonin, dopamine and norepinephrine re-uptake WO2010146025 More
  • Anti-inflammatory macrolide WO2010086349 More
  • 9-Deoxo- 9a-methyl- 9a- aza- 9a-homoerythromycin a derivatives for the treatment of neutrophil dominated inflammatory diseases WO2010086350 More
  • 3′-N-substituted 9-deoxo-9a-methyl-9a-aza-homoerythromycin having antimalarial activity WO2010086351 More
2009
  • Spiro compounds useful as antagonists of the H1 receptor and their stereoselective preparation, pharmaceutical compositions and use in the treatment of sleep disorders WO2009016084 More
  • 9-Deoxo-9a-methyl-9a-aza-9a-homoerythromycin a derivatives and their use for the treatment of malaria WO2009016142 More
  • 2′-O, 3′ -N-bridged macrolides WO2009130189 More
2007
  • Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract WO2007093840 More
  • 9a-Substituted azalides for the treatment of malaria WO2007125414 More
2006
  • Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract WO2006018698 More
  • Novel antimalarial 9a-carbamoyl-aminoalkyl and 9a-thiocarbamoyl-aminoalkyl azalides WO2006085228 More
  • Monoamine reuptake inhibitors for treatment of cns diseases and disorders WO2006109190 More
  • Macrolones – amino substituted quinolones WO2006050942 More
  • Macrolones WO2007054296 More
  • Macrolone compounds WO2006050943 More
  • Macrolides with anti-inflammatory activity WO2006087644 More
  • Macrolide compounds containing biotin and photo-affinity group for macrolide target identification WO2006106440 More
  • Ether linked macrolides useful for the treatment of microbial infections WO2006120541 More
  • Decladinosyl macrolides with anti-inflammatory activity WO2006077501 More
  • Conjugates with anti-inflammatory activity WO2006046123 More
  • Bis-(coumarin) compounds with anti-inflammatory activity WO2006111858 More
  • Anti-inflammatory macrolide conjugates WO2006075255 More
  • Anti-inflammatory conjugates of macrolides and coumarins WO2006092739 More
  • 9a-Carbamoyl and thiocarbamoyl azalides with antimalarial activity WO2006087642 More
  • 9a-carbamoyl and thiocarbamoyl azalides with anti-inflammatory activity WO2006097849 More
  • 9a-Carbamoil-γ-aminopropyl- and 9a-thiocarbamoyl-γ-aminopropyl-azalides with antimalarial activity WO2006075256 More
  • 4″ Amino linked macrolides useful for the treatment of microbial infections WO2006120545 More
2005
  • Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders WO2005072728 More
  • Use of 3-aza-1-oxa-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders WO2005049036 More
  • Use of 2-thiadibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders WO2005041856 More
  • Use of 1-thia-3-aza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorder WO2005049020 More
  • Use of 1-oxa-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders WO2005049010 More
  • Use of 1-aza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders WO2005049011 More
  • Use of 1,3-diaza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders WO2005049016 More
  • Use of 1,2-diaza-dibenzo[e,h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders WO2005049015 More
  • Supstituted furochromene compounds, their preparation and antiinflammatory activity WO2005010007 More
  • Substituted furochromene compounds of antiinflammatory action WO2005010006 More
  • Solid state forms of (-)-(1R,2S)-2-amino-4-methylene-cyclopentanecarboxylic acid WO2005100302 More
  • Preparation of 1-aza-2-oxa-dibenzo[e,h]azulenes and their use for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders WO2005049623 More
  • Furochromen derivative with antiinflamatora effect WO2005095411 More
  • Ester linked macrolides useful for the treatment of microbial infections WO2005108412 More
  • Carbamate linked macrolides useful for the treatment of microbial infections WO2005108413 More
2004
  • Substituted 9a-N-{N’-[4-(sulfonyl)phenylcarbamoyl]} derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A WO2004043985 More
  • Substituted 9a-N-[N’-(benzenesulfonyl)carbamoyl-γ-aminopropyl] and 9a-N-[N’-(β-cyanoethyl)-n’-(benzenesulfonyl)carbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A WO2004043984 More
  • N”-substituted 9a-N-(N’-carbamoyl-γ-aminopropyl), 9a-N-(N’-thiocarbamoyl-γ-aminopropyl), 9a-N-[N’-(β-cyanoethyl)-N’-carbamoyl-γ-aminopropyl] and 9a-N-[N’-(β-cyanoethyl)-N’-thiocarbamoyl-γ-aminopropyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerithromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A WO2004052904 More
  • Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use WO2004005309 More
  • Novel compounds, compositions as prodrug carriers for steroid/nonsteroid anti-inflammatory, antineoplastic and antiviral active molecules WO2004005313 More
  • Novel 14 and 15 membered-ring compounds WO2004101586 More
  • Novel 14 and 15 membered ring compounds WO2004101588 More
  • New compounds, compositions and methods for treatment of inflammatory diseases and conditions WO2004005310 More
  • New 3-decladinosyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromicin A 9a,11-cyclic carbamates WO2004029067 More
  • New 3-decladinosyl 9a-N-carbamoyl and 9a-N-thiocarbamoyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a homoeritromycin A WO2004101591 More
  • Macrolides substituted at the 4″-position WO2004101585 More
  • Macrolide conjugates with antiinflammatory activity WO2004094449 More
  • Derivatives of 1-thiadibenzoazulenes and their biological activity WO2004078763 More
2003
  • Thienodibenzoazulene compounds as tumor necrosis factor inhibitors and their preparation, pharmaceutical compositions and use in the treatment of inflammation US20030153750 More
  • 2-Tia-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof WO03084962 More
  • 1-Thia-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof WO03099827 More
  • 1-Oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof WO03097649 More
  • 1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof WO03084964 More
  • 1-Aza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof WO03097648 More
  • 1,3-Diaza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof WO03099823 More
  • 1,2-Diaza-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof WO03099822 More
  • 1- or 3-Thia benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof WO03084961 More
2002
  • Azithromycin for treatment of noninfective inflammatory diseases More
  • Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy WO02055531 More
  • 9a-N-[N’-(phenylsulfonyl)carbamoyl]-derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and of 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerithronolide A WO02068438 More
  • Macrolides WO0232917 More
2001
  • Thienodibenzoazulene compounds as tumor necrosis factor inhibitors WO0187890 More
2000
  • Novel 8a- and 9a-15-membered lactams WO00063223 More
  • Halo derivatives of 9-deoxo-9a-aza-9a-homerythromycin A WO00066603 More